Kellerhals Carrard advises existing investors in Oviva’s Series D

In healthcare, the hardest problems aren’t solved in a single breakthrough. They’re solved by building models that work every day, for millions.
 Oviva is doing exactly that: scaling evidence based support for people living with chronic and weight related conditions by combining multidisciplinary care teams with digital programmes and AI enabled personalisation. The approach is designed to work alongside healthcare systems and fit into patients’ daily lives.
 
Today, Oviva announced its Series D round of USD 220m, comprising a mix of primary and secondary capital. The round was led by health tech growth investor Kinnevik, with participation from Planet First Partners, A.P. Moller Holding, Lunate, EGS Beteiligungen AG, Norrsken and Sofina.
For long term backers, the milestone reflects years of mission driven execution. Oviva’s journey spans from Seed to Series D. In 2025, the company reached a remarkable marker of scale and treated its millionth patient.
 As Kai Eberhardt, Co Founder and CEO, put it: “What matters most is impact: helping people live healthier lives, at scale.”
 
Kellerhals Carrard advised the existing institutional investors MTIP, AlbionVC, Earlybird, F-Prime Capital, Eight Roads and Sofina in this transaction.
 KC core team comprised of: Dr. Karim Maizar (Partner, Corporate/VC), Luana Stämpfli (Partner, VC/M&A) and Arnault Eckert (Associate, Corporate/VC).
 
Warm congratulations to Oviva, Kai Eberhardt and his team and everyone behind this achievement — and to our investor clients MTIP, AlbionVC, Earlybird, F-Prime Capital, Eight Roads and Sofina for their continued support of a company delivering measurable impact at scale.